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A B S T R A C T
Background: The growing number of incident cases of gastric cancer along with improved survival result in a
rising population of survivors at risk of second primary cancers (SPC). We estimated the cumulative incidence of
metachronous (diagnosed>2 months after ﬁrst primary cancer [FPC]) SPC in gastric FPC patients and com-
pared the incidence of metachronous SPC with that expected in the general population.
Methods: A cohort of gastric FPC patients from the North Region Cancer Registry of Portugal, diagnosed in
2000–2006 (n = 7427) was followed to 31 December 2010 for synchronous and metachronous SPCs.
Cumulative incidence of metachronous SPCs taking into account death as a competing event and standardized
incidence ratios (SIR) of metachronous SPCs were estimated.
Results: Overall, 331 (4.5%) patients developed an SPC (26.9% synchronous and 73.1% metachronous). Over
half of the SPCs occurred in digestive organs. Among men, the most frequent were colon, prostate, and trachea,
bronchus and lung; in women, colon, breast and thyroid were the most common. The 10-year cumulative in-
cidence of metachronous SPC for males was 5.7% and for females 3.5%. The SIR for all cancers was 1.30 in males
and 1.20 in females. Among both sexes, signiﬁcantly higher SIRs were observed for cancers of the oesophagus
(males: 4.99; females: 8.03), small intestine (males: 11.04; females: 13.09) and colon (males: 2.42; females:
2.58).
Conclusions: Patients with a gastric FPC were found to be at increased risk of developing SPC, mainly in digestive
organs, when compared to the general population. Close surveillance of these patients may allow early detection
of SPC.
1. Introduction
Gastric cancer is the ﬁfth most common and third leading cause of
cancer death worldwide [1]. Downward trends in mortality have been
observed, however, the declines have become gradually smaller in some
countries and a levelling oﬀ may be expected in high-income settings
[2]. In Portugal, gastric cancer ranks ﬁfth in incidence and mortality
[1]. Despite the latter showing a decreasing trend in the past few
decades [3], Portugal continues to present the highest mortality rates in
Western Europe [4] and there is a large variation within the country; in
the North region, incidence and mortality are much higher [3,5].
Though survival from gastric cancer remains poor [6], an increase
has been observed due to gradual improvements in diagnosis and
treatment [7]. These survivors are at increased risk for several adverse
health events, including recurrence of ﬁrst primary cancer (FPC), car-
diovascular diseases or second primary cancer (SPC) [8]. Between 1995
and 1999, the stomach was the ﬁfth most frequent FPC site of multiple
tumours, accounting for 4.1% of all subsequent cancers in Europe [9].
In the United States of America (USA), 4.0% of patients with an initial
diagnosis of stomach cancer from 1973 to 2000 and a maximum follow-
up of 27-years developed a subsequent primary cancer [8]. In Northern
Portugal, stomach cancer has been shown to be the third most common
FPC for patients diagnosed with a subsequent tumour between 2000
and 2003, contributing to an estimated 9.5% of all multiple primary
cancers [10].
In the present study, we expanded previous observations in the
North of Portugal, by following for a maximum of 10-years a popula-
tion-based cohort of patients with a gastric FPC, diagnosed between
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2000 and 2006, for the occurrence of synchronous and metachronous
SPCs. Our aim was to estimate the 10-year cumulative incidence of
metachronous SPC, taking into account the competing event of death,
and to compare the incidence of metachronous SPC in gastric FPC pa-
tients with the expected incidence in a sex-, age- and calendar year-
matched population.
2. Methods
2.1. Study setting
Cancer data were provided by the North Region Cancer Registry
(RORENO), a population-based cancer registry established in 1988. The
registry covers the Northern region of Portugal, corresponding to ap-
proximately 3.3 million inhabitants, which is nearly one-third of the
Portuguese population. All incident cancers occurring in the area are
recorded by the registry, either directly from the main public hospitals
through a web-based platform, or based on hard copies of medical re-
ports from private hospitals and pathology laboratories. RORENO cal-
culates cancer incidence using estimates of the resident population in
the area covered by the registry each year, according to Statistics
Portugal. The results are expressed as an annual rate per 100000
person-years. Registration follows the International Agency for
Research on Cancer (IARC) rules which include four quality dimen-
sions: comparability, validity, timeliness and completeness. Registries
maintain quality through regular screening with pre-deﬁned algorithms
for validity and consistency [11]. From 1998 to 2002, RORENO fulﬁlled
IARC indices of data quality, which indicates a high degree of com-
pleteness of ascertainment [12,13].
2.2. Tumour classiﬁcation and deﬁnition of multiple primary cancers
Tumour topography and morphology were classiﬁed according to
the International Classiﬁcation of Diseases for Oncology, Third Edition
[14], and then recoded to the International Statistical Classiﬁcation of
Diseases and Related Health Problems 10th Revision [15].
SPC is a new primary cancer in a person with a history of malig-
nancy [16]. Multiple primary cancers were deﬁned according to the
guidelines proposed by the International Association of Cancer Re-
gistries (IACR) and IARC [17]. Brieﬂy, these guidelines consider pri-
mary cancers those that originally developed in an organ or tissue, not
being an extension, recurrence or metastasis. Diﬀerent morphologies
(even with the same topography) or dissimilar topographies should be
regarded as multiple primary cancers, regardless of the time between
diagnoses, unless they correspond to systemic cancers, which are con-
sidered the same cancer.
2.3. Study design
All primary invasive tumours of the stomach (C16) diagnosed in
adults resident in the North of Portugal between 1 January 2000 and 31
December 2006 were identiﬁed (n = 8174).
We excluded patients who had a diagnosis of an FPC, except skin
non melanoma, previous to a stomach cancer (n = 428) and those
which could not be linked to the National Health System for assessment
of vital status (n = 319). The latter were not signiﬁcantly diﬀerent from
included participants regarding sex (men: 64.3% vs. 59.3%; p = 0.075)
but were signiﬁcantly older at diagnosis of FPC (median: 72 vs. 68;
p = 0.002), and had signiﬁcantly more gastric not otherwise speciﬁed
and less non-cardia tumours (90.6% vs. 66.3% and 5.6% vs. 27.9%,
respectively; p< 0.001).
The remaining patients (n = 7427) were followed to 31 December
2010, allowing for over 10-years of potential follow-up, until the di-
agnosis of an SPC or death, whichever occurred ﬁrst. The occurrence of
any subsequent cancer was ascertained by means of record linkage with
the list of cases registered by RORENO. Patients known to have died but
with an unknown date of death (n = 18), were imputed a follow-up
time equal to the median follow-up of the corresponding sex, 5-year age
group (from 15–19 to 70–74, and ≥75) and year of diagnosis.
Whenever more than two primary cancers were observed in the
same patient, only the ﬁrst was considered; third and subsequent pri-
maries were disregarded for the present analysis. Due to the thorough
evaluation of cancer patients during the initial medical work-up [8], we
classiﬁed SPCs as synchronous when diagnosed within two months of
the gastric FPC or metachronous otherwise, as previous studies on this
topic [8,10,18,19].
2.4. Statistical analysis
Patients' characteristics were presented as counts and proportions
for categorical variables, and median (percentile 25-percentile 75 [P25-
P75]) for quantitative variables. To compare quantitative and catego-
rical variables across groups, the Mann-Whitney test and Chi-square
test were used, respectively. Statistical signiﬁcance was considered
when p< 0.05. All reported p-values are two-sided. These analyses
were carried out separately for synchronous and metachronous SPCs.
Cumulative incidence and corresponding 95% conﬁdence intervals
(CI), stratiﬁed by sex, age and tumour location, for the occurrence of
metachronous SPC were calculated, with death as a competing event
according to the method introduced by Kalbﬂeisch and Prentice [20].
Brieﬂy, this method allows for patients who died to no longer be at risk
for an SPC by actively removing individuals from the risk sets; thus, it
diﬀers from the cumulative incidence estimated by the Kaplan-Meier
(KM) method, which treats competing events as censored at the time
they occurred. We show plots for metachronous SPCs and mortality
[21].
Standardized incidence ratios (SIR) and corresponding 95%CI were
computed to compare cancer incidence rates among gastric FPC with
those in the general population. SIRs were calculated by dividing the
observed number of metachronous SPCs by the expected number of
cases, in the same calendar year, if the cancer incidence rates in the
general population had been observed among survivors. The latter were
estimated by multiplying the cancer incidence in the general population
by the person-years at risk (PYAR) in the corresponding stratum; de-
ﬁned according to sex, 5-year age group (from 15–19 to 70–74, and
≥75 years) at FPC diagnosis and each individual calendar year
(2000–2010). PYAR were calculated from two months after the diag-
nosis of FPC until diagnosis of a metachronous SPC, death or end of
follow-up (31 December 2010), whichever occurred ﬁrst. The corre-
sponding stratum incidence of cancer among the general Northern
Portuguese population was acquired from RORENO (described in 2.1
Study setting) [22]. The 95%CIs were estimated assuming that the
observed number of cancers followed a Poisson probability distribution.
In addition, several sensitivity analyses were performed deﬁning
metachronous SPCs as diagnosed one month, six months and one year
after the gastric FPC.
Statistical analyses were conducted using STATA®11.2 and
R3.3.2 (cmprsk package). The study was approved by the Ethics
Committee of the Portuguese Institute of Oncology of Porto (Ref. CES
IPO: 173/2015) and the analyses were performed according to
RORENO guidelines ensuring the anonymity of information used.
3. Results
A total of 7427 cases of gastric FPC diagnosed between 2000 and
2006 were included. During follow-up, we found 331 (4.5%) SPCs, 242
(73.1%) were classiﬁed as metachronous (Fig. 1). When the time to
deﬁne SPCs was changed, the number of metachronous SPCs decreased
from 264 (79.8%) to 185 (55.9%) using one month and one year, re-
spectively (Appendix A).
Patientś characteristics are shown in Table 1. The median age at
diagnosis of FPC did not diﬀer between patients with and without an
S. Morais et al. Cancer Epidemiology 50 (2017) 85–91
86
SPC. More than half (59.3%) of the patients were male, with SPCs oc-
curring more often in men. The distribution of tumour location within
the stomach was similar between patients with a synchronous or me-
tachronous SPC and without an SPC. The median (P25-P75) follow-up
in patients without an SPC was 7.3 (5.5–8.9) years, with a synchronous
SPC was 0.1 (0.0–0.1) years, and 2.4 (1.0–4.7) years for patients with a
metachronous SPC.
The SPC distribution showed that the most common sites were di-
gestive organs (n = 169, 51.1%), over two-thirds were classiﬁed as
metachronous tumours. In men, the most frequent synchronous SPC
were the colon (n = 24, 42.9%), rectum (n = 5, 8.9%), and trachea,
bronchus and lung (n = 5, 8.9%); for metachronous SPC, the colon
(n = 35, 20.8%), prostate (n = 33, 19.6%), and trachea, bronchus and
lung (n = 22, 13.1%) were the most frequent. Among women, the
colon (n = 11, 33.3%), breast (n = 4, 12.1%) and non-Hodgkin
lymphoma (n = 3, 9.1%) were the most common synchronous SPC.
Colon (n = 20, 27.4%) and breast (n = 15, 20.5%) cancers occurred
frequently as metachronous SPC in women (Fig. 2). The most frequent
metachronous SPCs among both sexes remained the same regardless of
the time deﬁnition used (Appendix A). Among males, over 80% of SPCs
in the prostate, bladder, and liver and intrahepatic bile ducts were
metachronous tumours diagnosed more than six months after gastric
FPC diagnosis. In females, all rectum SPCs were synchronous tumours
diagnosed within one month of the gastric FPC; while all SPCs of the
cervix uteri, kidney, and trachea, bronchus and lung occurred over six
months following the gastric FPC.
The cumulative incidence of metachronous SPCs was calculated
with death as a competing event (Fig. 3). The overall 10-year cumu-
lative incidence of SPC was 4.8% (males: 5.7%; females: 3.5%); the
overall 10-year cumulative mortality was 69.5% (males: 72.0%;
Fig. 1. Flow chart of patient inclusion in the study
(Follow-up to 31 December 2010).
Table 1
Features of gastric cancer patients with synchronous and metachronous second primary cancers, and without a second primary cancer.
Total Patients without an SPC Patients with an SPC
N= 7427
(100.0%)
N = 7096 (95.5%) N = 331 (4.5%)
p-value Synchronous p-value Metachronous p-value p-value
N All SPC vs. 89 SynchronousSPC 242 Metachronous SPC Synchronous SPC
vs.
no SPC vs. no SPC vs. no SPC a Metachronous SPC
Age at diagnosis of GC,
years
68.0 (56.0–76.0) 68.0
(56.0–76.0)
0.206 69.0 (57.0–77.0) 0.843 67.0 (58.0–73.0) 0.106 0.236
(median [P25–P75])
Sex (N [%])
Males 4402 (59.3) 4178 (58.9) 56 (62.9) 168 (69.4)
Females 3025 (40.7) 2918 (41.1) 0.001 33 (37.1) 0.441 74 (30.6) 0.001 0.262
Tumour location (N [%]) b
Cardia 436 (5.9) 419 (5.9) 3 (3.4) 14 (5.8)
Non-cardia 2070 (27.9) 1983 (28.0) 26 (29.2) 61 (25.2)
Gastric NOS 4921 (66.3) 4694 (66.1) 0.633 60 (67.4) 0.597 167 (69.0) 0.629 0.56
Follow-up, years 7.0 (5.2–8.8) 7.3 (5.5–8.9) < 0.001 0.1 (0.0–0.1) < 0.001 2.4 (1.0–4.7) < 0.001 <0.001
(median [P25-P75]) c
Dead (N [%]) d 5426 (73.1) 5233 (73.8) < 0.001 61 (68.5) 0.268 132 (54.6) < 0.001 0.022
GC gastric cancer, NOS not otherwise speciﬁed, P25 percentile 25, P75 percentile 75, SPC second primary cancer.
a Patients without an SPC are those who survived more than two months after diagnosis of the FPC.
b Deﬁned as cardia (C16.0), non-cardia (fundus, C16.1; body, C16.2; pyloric, C16.3; pylorus, C16.4; lesser and greater curvature, C16.5–6) and other parts (C16.8–9) [15].
c Follow-up to 31 December 2010 until SPC, death or end of follow-up. Median follow-up time was estimated using the reverse Kaplan-Meier [45].
d Follow-up to 31 December 2010.
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females: 66.0%). Cumulative incidence estimates were signiﬁcantly
higher among males (p < 0.001) and increased with age (p for
trend = 0.065 and 0.556 for males and females, respectively); how-
ever, lower estimates were observed in the oldest age group. Among
men, non-cardia tumours showed the highest cumulative incidence and
in women, not otherwise speciﬁed tumours had the highest estimates
(Appendix B). Cumulative incidence estimates of metachronous SPCs at
1- and 3-years were higher when using the one month deﬁnition and
the highest at 10-years for one year metachronous SPCs in both males
and females (7.5 and 4.2%, respectively) (Appendix A). Cumulative
mortality was signiﬁcantly higher among men (p < 0.001) (Fig. 3)
though greater values were observed for older ages and cardia tumours
in both sexes (Appendix B).
SIRs (95%CI) for the most common metachronous SPCs are shown
in Fig. 4. In comparison with the general population, both male (1.30
[1.11–1.52]) and female (1.20 [0.94–1.51]) gastric FPC patients had an
increased risk of any type of cancer. Among both sexes, signiﬁcantly
higher SIRs (95%CI) were observed for cancers of the oesophagus
(males: 4.99 [2.66–8.54]; females: 8.03 [2.19–20.56]), small intestine
(males: 11.04 [4.05–24.03]; females: 13.08 [3.57–33.52]) and colon
(males: 2.42 [1.69–3.37]; females: 2.58 [1.58–3.98]). Males were also
at increased risk for non-Hodgkin lymphoma (SIR [95% CI] 2.53
[1.16–4.81]), and females cancer of the liver and intrahepatic bile ducts
(SIR [95% CI] 5.18 [1.07–15.15]). The incidence rate of any meta-
chronous SPC among males was higher than in the general population,
though the strength of the association decreased as the cut-oﬀ to deﬁne
metachronous SPCs increased, and signiﬁcantly higher SIRs were ob-
served for cancers of the oesophagus, small intestine and colon across
all four time deﬁnitions. For women, the incidence rate of any meta-
chronous SPC was only signiﬁcantly higher than in the general popu-
lation when metachronous SPCs were deﬁned using the one-month cut-
oﬀ, yet as observed in men, the strength of the association declined as
the time used to deﬁne metachronous SPCs increased; signiﬁcantly
higher SIRs were observed for cancers of the small intestine and colon
using all time deﬁnitions (Appendix A).
4. Discussion
The overall 10-year cumulative incidence of metachronous SPCs
and mortality were 4.8 and 69.5%, respectively. Compared to the
general population, gastric FPC patients had a signiﬁcantly increased
risk of metachronous SPCs, especially in other digestive organs, which
remained even when deﬁning these SPCs as more than one year post
diagnosis of the FPC.
Fig. 2. Synchronous and metachronous second primary cancersa in males and females.
aOesophagus (C15), Small intestine (C17), Colon (C18), Rectum (C19-C20), Liver and intrahepatic bile ducts (C22), Trachea, bronchus and lung (C33-C34), Breast (C50), Cervix uteri
(C53), Corpus uteri (C54), Ovary (C56), Prostate (C61), Kidney (C64), Bladder (C67), Thyroid (C73), Non-Hodgkin lymphoma (C82-C86, C96). Others: for both sexes− Lip, oral cavity
and pharynx (C1), Stomach (C16), Anus (C21), Gallbladder and biliary tract (C23-C24), Pancreas (C25), Skin (C43), Brain and Central Nervous System (C70-C72), Lymphoid leukaemia
(C91), Myeloid leukaemia (C92-C94); for males only − Nasal cavity and ear (C30-C31), Larynx (C32), Multiple myeloma (C90); for females only − Rectum (C19-C20), Vagina (C52),
Other and unspeciﬁed female genital organs (C57), Renal pelvis (C65), Adrenal gland (C74) [14].
Fig. 3. Cumulative incidence of metachronous second primary cancers, by sex, taking into account the competing event of death.
SPC second primary cancer.
*Note that a diﬀerent scale is used for the two outcomes.
S. Morais et al. Cancer Epidemiology 50 (2017) 85–91
88
Although some national studies analysing SPCs in gastric cancer
patients have been conducted in Sweden [23], Taiwan [24] and the
USA [25], comparisons are diﬃcult because of the varying diagnostic
and follow-up times, and most other studies are from single-institutions,
often with few SPCs. The proportion of SPCs diagnosed in patients with
gastric FPC in Northern Portugal was higher than the observed in
Sweden, where 962 (2.8%) SPCs were reported in 34506 people with
gastric cancer diagnosed from 1960 to 1981 and followed to December
31, 1981 [23], a longer period than that of our study. On the other
hand, our results are consistent with those from Taiwan, where over
2000 SPCs were observed during a follow-up of 47729 gastric FPC
patients diagnosed between 1997 and 2011 [24]. In the USA, among
33720 gastric FPC patients diagnosed from January 1992 to December
2012, 1838 patients (5.5%) developed metachronous SPCs after a
period of six months from diagnosis [25]. A previous study also from
the North of Portugal, though with a longer study period, had 78 (3.4%)
SPCs (73% were deﬁned as metachronous using a six month cut-oﬀ)
diagnosed in 2668 patients with gastric cancer between July 1974 and
December 1999 [26]; this overall estimate of SPCs is lower than ours.
This may be partially explained by improvements in survival of cancer
patients overtime [6,7] and the previous study only had follow-up of
patients from a single oncology specialized hospital, while our results
are from a population-based cancer registry. In general, the proportion
of SPCs that are synchronous varies from 11.4 to 47.9% [19,24], using a
two month and a one year deﬁnition, respectively. We found less than
one-third synchronous SPCs using a two month deﬁnition, while almost
half of all SPCs were diagnosed within the ﬁrst year of the gastric FPC.
The risk of metachronous SPCs after the diagnosis of gastric cancer
has been estimated in previous studies: in Korea, patients who under-
went curative resection of gastric cancer were retrospectively reviewed
showing a 5-year cumulative incidence of SPC of 1.4% [27], and in
Japan, the occurrence of second tumours at least six months following
resection of early gastric cancer was estimated at 5.0% after more than
10 years of follow-up [28]. Another study, from Korea, had an in-
cidence of 3.7% with a median time to the occurrence of metachronous
SPC six months or more after diagnosis of the gastric FPC of 3.3 years
(standard deviation: 2.6 years) [29]. Our overall cumulative incidence
of metachronous SPCs more than two months after the FPC was 3.1 and
4.8% at 5- and 10-years, respectively; corresponding estimates using a
six month cut-oﬀ to deﬁne SPCs were 3.3 and 5.4%, respectively.
The guidelines chosen to diagnose SPC may account for some of the
heterogeneity observed; compared to the Surveillance, Epidemiology,
and End Results Program coding rules, IARC/IACR rules are less com-
plex, have not changed over time and report fewer multiple primary
cancers [30]. The best interval to deﬁne SPCs as synchronous or me-
tachronous has also been disputed, ranging from one month to one year
[8,24,31]. Thus, we may have observed a smaller number of SPCs by
using the more restrictive IARC/IACR rules; using a two month gap to
classify tumours likely increased the proportion of metachronous SPCs.
However, we performed sensitivity analyses using diﬀerent time per-
iods to classify SPCs as synchronous or metachronous in order to in-
crease comparability with other studies, which use various time deﬁ-
nitions.
In published research, the frequency of ﬁnding SPC accompanying
gastric cancer is higher in male patients [24,27,28], in accordance with
our ﬁndings. Although SPCs have been related to age [24,28,32], we
found no diﬀerences between age at diagnosis in patients with and
without SPC. Additionally, there were no signiﬁcant diﬀerences in the
tumour site of the gastric FPC. Other studies have also not found dif-
ferences with regards to gastric cancer location [27,28,32].
In our study, the most common types of SPCs were digestive (colon,
oesophagus and rectum in males, and colon, oesophagus and small
intestine in females). Our data seems to be similar to the ﬁndings of
others, who also reported that digestive cancers, particularly of the
colon and rectum, are the most frequent in gastric cancer patients with
multiple malignancies [23,27,32]. The high incidence of these cancers
in gastric FPC patients may be due to the common carcinogenic process
and the same risk factors that aﬀect the gastrointestinal tract (e.g.:
contaminants such as N-nitroso compounds found in smoked foods,
preserved meats and some alcoholic beverages, diet, and smoking)
[33,34]. As cancer patients are under closer examination than the
general population, the observed increased risks of developing meta-
chronous SPCs in the oesophagus, small intestine and colon after di-
agnosis of gastric cancer may be due to follow-up of an FPC also in a
digestive organ [35]. Additionally, gradual improvements in gastric
cancer staging overtime, such as the increasing use of computerised
tomography scanning and endoscopic ultrasound [2], may have had
some role in the incidence of simultaneous primary cancers. Previous
research has also shown signiﬁcant excess risk for gastrointestinal
cancers in patients with a previous gastric cancer diagnosis [24,25].
Accordingly, a prior study in the North of Portugal including patients
diagnosed between 2000 and 2003 found that the most common SPC in
Fig. 4. Standardized incidence ratios and 95% conﬁdence interval of selected metachronous second primary cancers in patients with ﬁrst primary gastric cancer.
95% CI 95% conﬁdence interval, NA not applicable, SIR standardized incidence ratios; SPC second primary cancer.
aOesophagus (C15), Small intestine (C17), Colon (C18), Rectum (C19-C20), Liver and intrahepatic bile ducts (C22), Trachea, bronchus and lung (C33-C34), Breast (C50), Cervix uteri
(C53), Corpus uteri (C54), Ovary (C56), Prostate (C61), Kidney (C64), Bladder (C67), Thyroid (C73), Non-Hodgkin lymphoma (C82-C86, C96) [14].
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gastric cancer patients were also the colon and rectum [10]; however, it
did not show a signiﬁcant risk of SPCs diagnosed more than two or 12
months after the gastric FPC [36]. In the present study, because of the
larger sample size and longer follow-up period, we observed a sig-
niﬁcant increased risk of SPC after two months in males and though our
estimate for SPCs deﬁned using a 12 month gap was not statistically
signiﬁcant, it was more precise. The higher risk of other digestive
cancers developing in gastric FPC patients suggests the potential for
early detection through careful follow-up of these patients even fol-
lowing the ﬁrst year of diagnosis.
Among men, the occurrence of oesophageal, bladder, and trachea,
bronchus and lung cancers, which are strongly associated with smoking
[37], is in accordance with the frequency of those cancers in Northern
Portugal [22] and the frequency of tobacco consumption among men in
Portugal [38]. Expectedly, among females, the frequency of synchro-
nous and metachronous second breast cancers was high; while in males,
metachronous second prostate cancers were common, which is similar
to data from RORENO within the same period for the most frequent
neoplasm in each sex [22]. Although organized cancer screening pro-
grams in Northern Portugal are relatively recent [39], a previous study
based on a representative sample of the adult Portuguese population
showed a high use of breast, cervical and prostate cancer screening
[40]. Additionally, as cancer screening is more frequent among cancer
survivors than in the general population [41,42], a high frequency of
these cancers as SPCs may be expected. Nevertheless, our results es-
sentially reﬂect the fact that these cancers have some of the highest
incidence rates and no increased incidence was observed in comparison
with the general population.
The 10-year cumulative incidence of SPC two months post FPC di-
agnosis for males was 5.7% and for females 3.5%. We expect our re-
sults, which account for the competing event of death, to be lower than
previously estimated using the 1-KM estimator [43]. This is because
they would consider death as a non-informative censoring event where
censored patients are considered to have the same probability of ex-
periencing the event of interest, SPC, as those who remain in the risk set
[44]. Conceptually, this is an unrealistic situation as a patient who is
censored due to death will not develop an SPC. Since patients who will
never have an SPC are treated as if they could, the 1-KM estimator
overestimates the probability of SPC and underestimates the corre-
sponding survival probability [43]. Our results illustrate the need to
analyse the occurrence of SPC taking into account the competing event
of death since these are mutually exclusive.
The sample was obtained from RORENO, which is representative of
Northern Portuguese gastric cancer survivors though it is not re-
presentative of all of Portugal as the North has higher incidence rates of
gastric cancer compared to the rest of the country [5], thus extra-
polating these results to Portugal should be done cautiously. However,
our results are consistent with those observed in countries where gastric
cancer is frequent (e.g.: Taiwan, Japan and Korea). Our study has cer-
tain limitations. It is possible that the number of deaths was under-
estimated because of loss to follow-up of signiﬁcantly older patients;
however, less than 5% patients could not be linked thus we do not
expect this to signiﬁcantly change our results. Although we imputed
follow-up for some patients who did not have a date of death in the
National System Database, we do not believe that this would over-
estimate PYAR, which could have led to a larger number of expected
SPCs. Additionally, although the use of a population-based cancer
registry of this magnitude, allowed us to follow over 7000 gastric
cancer patients for at least four years and for a maximum of 10 years,
we were limited by the information available in the registry. Thus, we
were unable to assess cancer outcomes accounting for factors such as
family history, lifestyle (diet, alcohol and smoking), comorbidities and
treatment in the SIR calculations which have been shown by some
studies to be associated with SPCs [19,24]. Finally, our study is limited
in interpretation as complete data on histotype and stage of gastric
tumours are not available from RORENO.
The risk of distinct SPCs among gastric cancer patients is hetero-
geneous, highlighting the need to consider speciﬁc SPCs rather than the
overall risk. Though the survival of these patients remains poor [6], we
observed that they are at particularly higher risk of being diagnosed
again in other digestive organs. Additionally, the interval between the
gastric FPC and the diagnosis of an SPC is relevant, with over half of the
SPCs being diagnosed more than one year after the FPC. In conclusion,
our ﬁndings suggest that improvements in clinical practice via close
surveillance and counselling may result in earlier diagnosis of speciﬁc
SPCs and potentially better prognosis leading to reduce the overall
burden of cancer among this growing population.
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